Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Z, Barber B, et al. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract. 2011;7(3 Suppl):25s–30s.
   PubMedGoogle Scholar
• Sridharan M, Hubbard JM, Grothey A. Colorectal cancer: how emerging molecular understanding affects treatment decisions. Oncology. 2014;28(2):110–118.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the Colon or rectum (MCRC). J Clin Oncol. 2014;32(15_suppl):LBA3.
   Google Scholar
• Douillard J-Y, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–4705.
   PubMed Web of Science ®Google Scholar
• Andre T, Shiu K-K, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study. J Clin Oncol. 2020;38(18_suppl):LBA4.
   Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191.
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–746.
   PubMed Web of Science ®Google Scholar
• Negru S, Papadopoulou E, Apessos A, et al. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open. 2014;4(5):e004652.
   PubMed Web of Science ®Google Scholar
• Lenz H-J, Ou F-S, Venook AP, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (alliance). J Clin Oncol. 2019;37(22):1876–1885.
   PubMed Web of Science ®Google Scholar
• Cercek A, Braghiroli MI, Chou JF, et al. Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations. Clin Cancer Res. 2017;23(16):4753–4760.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Portnoy D, Obermannová R, et al. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Ann Oncol. 2019;30(1):124–131.
   PubMed Web of Science ®Google Scholar
• Battaglin F, Puccini A, Intini R, et al. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther. 2018;18(3):251–266.
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–3995.
   PubMed Web of Science ®Google Scholar
• Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results-a Turkish Oncology Group Trial. Oncology. 2013;85(6):328–335.
   PubMed Web of Science ®Google Scholar
• Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol. 2014;32(3_suppl):LBA387.
   Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–2247.
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer. 2013;12(3):145–151.
   PubMed Web of Science ®Google Scholar
• Varol U, Karaca B, Cakar B, et al. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis. Am J Clin Oncol. 2013;36(4):388–391.
   PubMed Web of Science ®Google Scholar
• Jang HJ, Kim BJ, Kim JH, et al. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget. 2017;8(42):73009–73016.
   PubMedGoogle Scholar
• Pericay C, Plazas JG, Montes AFF, et al. Real world data in colorectal cancer: a retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain—preliminary results (RWD-ACROSS study). J Clin Oncol. 2018;36(15_suppl):e18731.
   Google Scholar
• Alfonso PG, Garcia G, Gallego I, et al. Prognostic and predictive factors in metastasic colorectal cancer. J Clin Oncol. 2018;36(4_suppl):690–690.
   Web of Science ®Google Scholar
• Kuchel A, Ahern E, Collins S, et al. Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real‐world multi‐institution cohort study. Asia‐Pacific J Clin Oncol. 2021;17:84–93.
   Web of Science ®Google Scholar
• Schmidt T, Nienhüser H, Kuna C, et al. Prognostic indicators lose their value with repeated resection of colorectal liver metastases. Eur J Surg Oncol. 2018;44(10):1610–1618.
   PubMed Web of Science ®Google Scholar
• Eker B, Ozaslan E, Karaca H, et al. Factors affecting prognosis in metastatic colorectal cancer patients. Asian Pac J Cancer Prev. 2015;16(7):3015–3021.
   PubMedGoogle Scholar
• Siebenhüner AR, Güller U, Warschkow R. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases. BMC Cancer. 2020;20(1):246.
   PubMed Web of Science ®Google Scholar
• Zhang GQ, Taylor JP, Stem M, et al. Aggressive multimodal treatment and metastatic colorectal cancer survival. J Am College Surg. 2020;230(4):689–698.
   PubMed Web of Science ®Google Scholar
• Papaconstantinou I, Theodoropoulos G, Gazouli M, et al. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer. 2005;114(3):433–435.
   PubMed Web of Science ®Google Scholar
• Menon AG, Janssen-van Rhijn CM, Morreau H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest. 2004;84(4):493–501.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–618.
   PubMed Web of Science ®Google Scholar